New drug has been registered – Vildagliptin
Mir-Pharm announces successful registration of a new hypoglycaemic agent
Moscow, June 2024
Vildagliptin is a drug for the treatment of type 2 diabetes mellitus. It is a representative of highly selective dipeptidyl peptidase 4 (DPP-4) inhibitors (Glyptins). Vildagliptin inhibits DPP-4-mediated inactivation of GLP-1 and GIP, allowing GLP-1 and GIP to enhance insulin secretion in beta cells and suppress glucagon release by alpha cells, the islets of Langerhans in the pancreas. Vildagliptin has been shown to reduce hyperglycaemia in type 2 diabetes mellitus.
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.